Skip Navigation



NDT Advance Access published online on April 8, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn183
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/8/2457    most recent
gfn183v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fischereder, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fischereder, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Cancer in patients on dialysis and after renal transplantation

Michael Fischereder

Nephrologisches Zentrum, Medizinische Poliklinik Innenstadt, Klinikum der Ludwig-Maximilians-Universität München, Pettenkoferstr. 8a, 80336 München, Germany

Correspondence and offprint requests to: Michael Fischereder, Nephrologisches Zentrum, Medizinische Poliklinik Innenstadt, Klinikum der Ludwig-Maximilians-Universität München, Pettenkoferstr. 8a, 80336 München, Germany. Tel: +49-89-5160-3325; Fax: +49-89-5150-4485; E-mail: Michael.fischereder@med.uni-muenchen.de

Keywords: dialysis; immunosuppressive therapy; malignancy; renal transplantation; screening examination

The first 150 words of the full text of this article appear below.



   Introduction
 
During the past few years, it has become evident that standardized mortality rates for patients on dialysis and for renal transplant recipients are greatly increased not only due to excess cardiovascular disease and infection but also from mortality related to malignancies, i.e. solid organ cancers and lymphomas [1]. However, relative risks vary between dialysis and transplant patients and with ongoing efforts to further reduce cardiovascular morbidity, malignancy-related morbidity and mortality are of increasing importance. Due to different clinical implications one may differentiate between

  • Malignancy in dialysis patients
  • Donor-derived malignancy
  • De novo malignancy after renal transplantation



   Malignancy in dialysis patients
 
Almost 10 years ago, a large international registry analysis demonstrated a significant increase in cancer mortality for dialysis patients. Among European patients, the most frequent malignancies were located in the genitourinary and haematopoietic system and 73.9–16.7 deaths per 10 000 patient-years respectively were attributed to these malignancies [1]. As curative treatment allows . . . [Full Text of this Article]



   Donor-derived malignancy
 


   De novo malignancy
 


   Risk factors and tumour development
 


   Screening examinations with special reference to renal patients
 


   Immunosuppressive management
 


   Progressive tumours
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?